Management of a complex scalp defect.
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003399:Craniotomy; D003646:Debridement; D004388:Dura Mater / Q000601:surgery; D005909:Glioblastoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D006801:Humans; D008297:Male; D008866:Microsurgery; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D011183:Postoperative Complications / Q000209:etiology / Q000601:surgery*; D018714:Radiotherapy, Adjuvant; D012086:Reoperation; D012307:Risk Factors; D012535:Scalp / Q000187:drug effects / Q000528:radiation effects / Q000601:surgery*; D016038:Skin Transplantation; D013524:Surgical Flaps / Q000098:blood supply*; D013529:Surgical Wound Dehiscence / Q000209:etiology* / Q000601:surgery*; D014945:Wound Healing / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab